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In a recent issue of Circulation, Verma et al. (1) uncover 
a new interleukin-10 (IL-10)-dependent mechanism 
inhibit ing f ibrosis  in pressure overloaded mouse 
myocardium. In this study, pressure overload was achieved 
in wild-type (WT) and IL-10 knockout (IL-10KO) mice 
by transverse aortic constriction (TAC), a widely used 
experimental mouse model that creates pressure overload-
induced left ventricular hypertrophy, leading to heart 
failure. IL-10KO mice displayed more bone marrow (BM)-
derived fibroblast progenitor cell mobilization and homing 
to the heart. Chimeric IL-10KO mice with WT BM 
were protected against TAC-induced cardiac fibrosis and 
presented improved heart function. Verma et al. (1) found 
out that IL-10 inhibits homing and trans-differentiation 
of BM-derived fibroblast progenitor cells (FPC) in 
myofibroblasts, major effector cells of cardiac fibrosis. In 
vitro experiments performed on FPC isolated from mouse 
BM (prominin 1+ CD45+ cells) indicated that IL-10 could 
suppress the expression of the fibrosis-associated miR-21 in 
response to transforming growth factor-β (TGF-)β.
Cardiac fibrosis is associated with nearly all forms of 
heart disease. It is a common feature of several pathological 
conditions including myocardial infarction, pressure 
overload, hypertrophic cardiomyopathy, viral infections, 
toxic insults, or metabolism disorders. In contrast to 
physiological cardiac remodeling necessary for post-injury 
tissue healing, pathological cardiac fibrosis is characterized 
by excessive deposition of extracellular matrix (ECM) 
proteins, which reduces ventricular compliance and cardiac 
function, leading to heart failure. 
To date, there is no generally accepted therapy to treat or 
hinder cardiac fibrosis. The study of Verma et al. unravels 
potential therapeutic cellular and molecular targets, which 
can have broad clinical impact. Indeed, due to epidemics of 
diabetes, obesity, population aging, and medical advances 
(more people survive a heart attack), the number of people 
diagnosed with heart failure is steadily increasing and 
projected to rise by 46 percent by 2030, affecting more than 
8 million people (American Heart Association’s 2017 Heart 
Disease and Stroke Statistics Update) (2). 
In a general manner, organ fibrosis is characterized 
by the destruction of normal organ architecture and 
consequent decline of its function. This is a common final 
stage of long-lasting tissue fibrosis, resulting from a sum 
of minor injuries over a life time, progressive disturbance 
of the balance between the synthesis and degradation of 
ECM components, and production of an excessive amount 
of ECM by activated myofibroblasts. Myofibroblasts 
are α-smooth muscle actin (α-SMA) positive, spindle, or 
stellate-shaped cells. Their origin is not clear, they may arise 
by the phenoconversion of permanent cellular constituents 
of the heart, including cardiac fibroblasts, myocytes, 
endothelial cells [via endothelial to mesenchymal transition 
(EndMT)], and vascular smooth muscle cells, from 
stem cells, or from BM-derived circulating progenitors. 
Activated myofibroblasts can be produced in response to 
profibrotic mediators, such as TGF-β, growth factors, and 
inflammatory cytokines that are produced by various cell 
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types, including myocytes, resident fibroblasts, endothelial 
cells, and infiltrating immune cells. However, the relative 
contribution of the recruited and resident cell types to the 
activation of myofibroblasts remains unclear. 
Verma et al. (1) show that TAC induces homing of 
FPC to the heart and their trans-differentiation into 
myofibroblasts, which can be inhibited by IL-10. They 
identified a TGFβ-Smad2/3 signaling-mediated miRNA-21 
maturation as a novel mechanism by which IL-10 might 
inhibit BM-FPC-mediated cardiac fibrosis in the pressure-
overloaded myocardium.
TGF-β-mediated signaling pathways differentiate 
myof ibrob la s t  f rom the i r  precur sor s .  A l though 
phosphorylation of Smad2/3 is the classical pathway 
activated downstream of TGF-β receptors I and II, TGF-β 
can also promote some non-canonical signaling pathways 
including the activation of extracellular signal-regulated 
kinase (ERK)/cJun/p38 mitogen activated protein kinases. 
Whether IL-10 can also inhibit this pathway has not 
been assessed in Verma et al. (1). Likewise, since growth 
factors including platelet-derived growth factor (PDGF), 
connective tissue growth factor (CTGF), insulin-like growth 
factor (IGF), fibroblast growth factor (FGF), and epidermal 
growth factor (EGF) also contribute to the activation of 
myofibroblasts, it would be interesting to study the effect 
of IL-10 on these pathways. Finally, it has recently been 
reported that myofibroblast phenoconversion may proceed 
through the activation of a CXCL12/CXCR4 axis, which 
promotes signaling through the EGFR and downstream 
MEK/ERK and PI3K/Akt pathways, independently of 
TGF-β or Smad signaling (3).
The recruitment of innate immune cells in injured tissues 
plays an important role in the fibrosis process. Macrophages 
can indeed produce TGF-β and other profibrotic cytokines, 
therefore participating in myofibroblast activation. 
Recent evidence indicate that neutrophils can also be 
involved in the scenario by playing both beneficial and 
detrimental effects. Neutrophils contribute to infarct 
healing by affecting monocyte/macrophage recruitment and 
polarization in the ischemic myocardium (4). Conversely, 
changes in circulating neutrophils predict negative post-
ischemic ventricular remodeling (4). Chronic inflammation 
drives pathological cardiac remodeling (5). We can thus 
reason that a chronic low-grade inflammatory state is 
likely to promote pathological cardiac remodeling by 
direct effects of neutrophils and macrophages and pro-
inflammatory cytokines (e.g., IL-6, IL-1β, TNF-α) on 
fibrosis (6). For instance, since elderly people are more 
susceptible to heart failure, this mechanistic link could be 
particularly relevant to the process of aging-related cardiac 
fibrosis. Indeed, aging is characterized by the progressive 
functional decline of many interrelated physiological 
systems. In particular, aging is associated with the 
development of a systemic state of low-grade inflammation, 
and with progressive deterioration of metabolic function. 
In fact, persistent expression of a NLRC4 inflammasome 
gene module in older individuals and subsequent 
expression of the pro-inflammatory cytokine IL-1β 
was found to be correlated with metabolic dysfunction, 
oxidative stress and a lack of familial longevity (7). 
In older person, the balance between innate immunity and 
adaptive immunity shifts toward innate immunity, with 
a decrease in lymphocytes that may be accompanied by 
an increase in neutrophil counts. Interestingly, a recent 
study demonstrated a role for neutrophil extracellular 
traps (NETs) in cardiac fibrosis. This phenomenon 
depends on the enzyme peptidylarginine deiminase 4 
(PAD4) that citrullinates histones, leading to subsequent 
chromatin decondensation and NET formation (8). 
Mice deficient for PAD4 were protected against aging-
related heart fibrosis and they maintained cardiac function 
longer than WT mice. Neutrophils from older mice were 
more prone for PAD4-mediated histone citrullination and 
NET formation compared with young mice. In addition, 
this study showed that NETing neutrophils are recruited 
to the heart upon ascending aortic constriction, with 
extracellular chromatin being injurious to the heart and 
detrimental to its function. Neutrophils are a major source 
of IL-10 upon tissue injury (9), and chronic inflammation 
induces a switch in neutrophil phenotype, potentially 
leading to the production of circulating IL-10 secreting 
neutrophils. However, whether neutrophils exert anti- or 
pro-fibrotic functions in the settings of pressure overload-
induced cardiac fibrosis remains unclear. Importantly, 
the cellular source of IL-10 has not been identified in the 
study of Verma et al. (1). Assessing whether IL-10 secreting 
neutrophils are produced during acute and chronic cardiac 
fibrosis, and whether they could suppress FPC homing to 
the heart and their trans-differentiation into myofibroblasts 
requires further investigation. 
In mice, the same team and others showed that IL-
10 treatment attenuates both myocardial infarction and 
pressure overload-induced heart inflammation and improved 
cardiac function (10-12). Similarly, IL-10 administration 
to mice suffering from autoimmune myocarditis results 
in a significant decrease of myocardial inflammation and 
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fibrosis, as well as prevent the relapse of the left ventricular 
function and increased the ejection fraction (13). The 
study of Verma et al. (1) nicely indicates that IL-10 holds 
pertinent therapeutic potential for treatment of heart failure 
by its strong inhibitory role in BM-FPC-mediated fibrosis 
in pressure-overloaded myocardium. Clinical trials are in 
progress investigating the effect of the supplementation 
of IL-10 in Crohn’s diseases (14). In heart disease, further 
preclinical and clinical studies are certainly needed to 
identify the cellular source and targets of IL-10, to elucidate 
its precise role in the suppression of cardiac inflammation 
and fibrosis, and to estimate its potential therapeutic 
effectiveness.
In Verma et al. (1), the analysis of miRNA expression 
profiles in BM-FPC isolated from IL-10KO mice revealed 
upregulation of the pro-fibrotic miR-21 (15). The authors 
then showed that IL-10 can reduce miR-21 levels by 
inhibiting TGF-β-Smad2/3 signaling. Several experimental 
studies in mice found an association between increased 
miR-21 levels and myocardial fibrosis, a process relying 
on TGF-β and EndMT of endothelial cells (16) or on 
osteopontin, through the fibrotic MAPK-SMAD7 and anti-
apoptotic PDCD4-PTEN pathways (17). Interestingly, 
in vivo silencing of miR-21 could prevent both the 
development of angiotensin II and pressure overload-
induced cardiac fibrosis (17,18). The study of Verma et al. (1) 
uncovers an upstream inhibitory mechanism of pathological 
miR-21 dysregulation with potential larger impact on the 
fibrotic process. 
In the same line of research, using a rat model of 
chronic heart failure, a recent study showed that miR-
487b ameliorates cell apoptosis, inflammatory reaction of 
myocarditis, and fibrosis through inhibiting the IL-33/
ST2 pathway by suppressing IL-33 (19). This finding is 
of particular interest in view of the association of the IL-
33/ST2 pathway with the severity of heart failure clinical 
course and decline of cardiac function in heart failure 
patients. Strong evidence indicates that intramyocardial 
IL-33/ST2 signaling plays a crucial cardioprotective role 
during mechanical overload (20). Cardiac fibroblasts are 
a major source of IL-33. Furthermore, it has been shown 
that endothelial-specific deletion of IL33 or cardiomyocyte-
specific deletion of ST2 exacerbated pressure overload-
induced cardiac hypertrophy (21). Although further studies 
are required to elucidate the mechanisms linking miR-487b, 
IL-33/ST2 to the fibrotic processes, we can anticipate that 
silencing miR-487b could represent another potential anti-
fibrotic therapeutic approach with distinct mechanism of 
action. Also, detailed studies of intramyocardial functional 
interactions between IL-10 and IL-33-dependent pathways 
in specific cell types are awaited. Indeed, it is worth noting 
that broad inhibition of TGF-β early postinfarction has 
worsened post-myocardial infarction remodeling, while 
targeted suppression in the myocyte could be beneficial (22). 
Rather than by altering fibrosis, myocyte-selective TGF-β 
inhibition augments the synthesis of several protective 
cytokines, such as thrombospondin 4, IL-33, follistatin-like 
1, and growth and differentiation factor 15, an inhibitor of 
neutrophil integrin activation and migration. It turned out 
that myocyte-expressed TGF-β regulates acute neutrophil 
inflammatory response in ischemic hearts. These findings 
highlight the importance of cell-specific targeting of 
signaling pathways, such as those driven by TGF-β in the 
search of a potent therapeutic strategy against maladaptive 
cardiac remodeling. The novel insight provided by the 
study of Verma et al. (1) is in accordance with this concept. 
Specific targeting of myofibroblasts using IL-10 or miR-
21 antagomirs could be considered a valuable approach to 
counteract excessive ECM production and prevent heart 
failure.
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